CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: Cellectis bioresearch, the specialist in genome customization and commercial subsidiary of Cellectis (Paris:ALCLS) (Alternext: ALCLS), announces that it has been awarded a contract to provide services to the National Institutes of Health (NIH) and certain other government agencies. This multiple award, indefinite delivery/indefinite quantity (IDIQ) contract, has a maximum order limit of $9,509,000 over a period of five years. Under the terms of the contract, the scope of work includes generation of induced pluripotent stem (iPS) cell lines of clinical grade and differentiation of iPS cells toward specific tissue cell type of clinical grade.
